U.S. markets open in 4 hours 35 minutes
  • S&P Futures

    -5.75 (-0.14%)
  • Dow Futures

    -71.00 (-0.21%)
  • Nasdaq Futures

    -36.25 (-0.30%)
  • Russell 2000 Futures

    +1.00 (+0.05%)
  • Crude Oil

    +0.18 (+0.22%)
  • Gold

    +30.80 (+1.75%)
  • Silver

    +0.48 (+2.22%)

    +0.0034 (+0.32%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.91 (-4.16%)

    +0.0087 (+0.73%)

    -1.7090 (-1.24%)

    +240.22 (+1.42%)
  • CMC Crypto 200

    +4.54 (+1.13%)
  • FTSE 100

    +0.69 (+0.01%)
  • Nikkei 225

    +257.09 (+0.92%)

Corporate News Blog - Moleculin Biotech Announces Scientific Support for Research Endeavor at Mayo Clinic

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Moleculin Biotech, Inc. (NASDAQ: MBRX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MBRX. The Company announced on June 26, 2017, that it has entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin's WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin is basically a preclinical pharmaceutical Company which excels in the development of anti-cancer drug candidates, where some of them are on behalf of the M.D. Anderson Cancer Center. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBRX. Go directly to your stock of interest and access today's free coverage at: http://protraderdaily.com/optin/?symbol=MBRX.

The Announcement

According to the Company, Mayo Clinic physicians and scientists have requested Moleculin to supply them with WP1066 for preclinical testing for the potential treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor. According to the Company's studies, the DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3. The primary target for WP1066 is the cell-signaling protein, called STAT3, where the preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in-vitro and in-vivo tumor models.

According to multiple Independent research reports, WP1066 is now capable of tumor suppression in xenografts of human brain tumors transplanted into mice. Moleculin stated that it focuses on WP1066, as a potential treatment for DIPG, along with the physician efforts of multiple researchers at the M.D. Anderson Cancer Center, to secure an IND to study and validate the potential importance of WP1066 in the treatment of complicated tumors.

Moleculin Biotech

Moleculin is a preclinical stage pharmaceutical Company aimed at the development of anti-cancer drug candidates, where some of them are derived from M.D. Anderson Cancer Center. The Company's lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML). The Company additionally holds two preclinical small molecules under its portfolio, where one of them is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the activation of the patient's own immune system. On the other hand, the other small molecule portfolio member targets the metabolism of the tumor and prevents its further growth.

On June 15, 2017, the Company announced that it has asked its contract research organization (CRO), Theradex Systems, Inc., to expand its engagement with clinical sites in Poland for the planned Phase-I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin stated that in Poland, patients with AML have less access to clinical trials than those in the US. Through this approach, the Company plans to make it easier to recruit an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin will expand its partnership and engagement with Theradex, and ensure tight coordination of clinical activity between the US and Poland.

Last Close Stock Review

On Tuesday, June 27, 2017, the stock closed the trading session at $1.98, surging 30.26% from its previous closing price of $1.52. A total volume of 25.26 million shares have exchanged hands, which was higher than the 3-month average volume of 664.62 thousand shares. Moleculin Biotech's stock price skyrocketed 141.46% in the last one month, 76.79% in the past three months, and 1.02% in the previous six months. The stock currently has a market cap of $36.27 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily